.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Chinese Patent Office
US Department of Justice
Harvard Business School
Boehringer Ingelheim
Cerilliant
AstraZeneca
US Army
Johnson and Johnson
Covington

Generated: June 24, 2017

DrugPatentWatch Database Preview

Claims for Patent: 4,087,547

« Back to Dashboard

Claims for Patent: 4,087,547

Title: Hexahydro-dibenzo[b,d]pyran-9-ones in treatment of glaucoma
Abstract:Use of 1-hydroxy-3-alkyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones in treatment of glaucoma.
Inventor(s): Archer; Robert A. (Indianapolis, IN), Lemberger; Louis (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:05/658,441
Patent Claims: 1. A process for reducing intraocular pressure in mammals which comprises administering to a mammal with an elevated intraocular pressure an intraocular pressure reducing dose of a compound represented by the formula ##STR9## wherein R' is either C.sub.7 -C.sub.10 normal alkyl or is the group ##STR10## wherein R" is C.sub.2 -C.sub.7 alkyl and R.sup.v is H or methyl, wherein both R groups are identical and are H or methyl and wherein R'" is H or C.sub.1 -C.sub.4 alkanoyl, in an amount effective to releive intraocular pressure.

2. A process according to claim 1 in which a dose of from 0.1 to 100 mgs per day of the drug is administered.

3. A process according to claim 1 in which a dose of from 1 to 20 mgs. per day of the drug is administered.

4. A process according to claim 1 in which the drug is administered by the oral route.

5. A process according to claim 1 in which dl-trans-1-hydroxy-3-(1',1'-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-6,6- dimethyl-9H-dibenzo[b,d]pyran-one is administered.

6. A process according to claim 1 in which dl-trans-1-hydroxy-3-(1',2'-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-6,6- dimethyl-9H-dibenzo[b,d]pyran-9-one is administered.

7. A process according to claim 1 in which dl-trans-1-hydroxy-3-(1'-methylheptyl)-6,6a,7,8,10,10a-hexahydro-6,6-dimet hyl-9H-dibenzo[b,d]pyran-9-one is administered.

8. A process according to claim 1 in which the drug is administered topically to the eye.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Fish and Richardson
Merck
Baxter
Federal Trade Commission
US Army
Daiichi Sankyo
Cerilliant
Dow
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot